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Immune complex glomerulonephritis in C4- and C3-deficient mice. In
this study, we examined the roles of C4 and C3 in immune complex
glomerulonephritis by actively immunizing C4-deficient (C4 2/2), C3
deficient (C3 2/2) and wild-type mice with apoferritin. Wild-type animals
with an intact complement system produced anti-apoferritin IgG and IgM
antibodies, and developed mesangial proliferative glomerulonephritis
characterized by hypercellularity, matrix expansion, deposition of IgG,
IgM, IgA and C3, and the presence of electron dense deposits. In the
majority of animals, the peripheral capillaries also contained IgG, C3 and
subendothelial and subepithelial electron dense deposits. In contrast to
wild-type animals, all apoferritin-immunized C4 2/2 and C3 2/2 mice
had serum cryoprecipitates containing polyclonal IgM and the variable
presence of polyclonal IgG. These animals also developed immune
complex glomerulonephritis, but their disease manifestations were dis-
tinctly different from that of their wild-type littermates. In apoferritin-
immunized C4 2/2 and C3 2/2 mice, IgG was either absent or present
in reduced quantities in glomeruli, yet IgM and IgA were present in
greater intensity in glomeruli. Capillary wall IgG deposits were absent in
all C4 2/2 and C3 2/2 animals. C4 2/2 animals also had significant
glomerular C3 deposition, hypercellularity and neutrophil infiltration,
which were not present in C3 2/2 animals. These results illustrate the
complex interplay between the effects of complement to process immune
complexes and to lead to inflammation and tissue injury.
The complement system consists of over 30 plasma and cell-
associated proteins. This system is tightly regulated, being con-
strained in its activation, as well as being inhibited by a number of
regulatory proteins once activation occurs. For the most part, the
activation of complement is proinflammatory, leading to recruit-
ment and stimulation of neutrophils and monocytes, as well as to
direct tissue damage [1, 2]. Furthermore, an intact complement
system is necessary for an appropriate and optimal humoral
immune response [3–6]. Since the early studies performed by
Kurtz and Donnel [7], and Unanue and Dixon [8], and later
studies by Salant and coworkers [9], a considerable amount of
research has been performed in experimental glomerular disease
models showing that complement activation is pathogenic. By
extrapolation to human glomerular diseases in which complement
activation products are present in glomeruli, and in some in-
stances, systemic complement consumption is apparent, comple-
ment is likely to be pathogenic in these disorders.
On the other hand, immune complex disease commonly occurs
in patients with complete deficiencies of any one of the early
classical pathway components, C1 (C1q or C1r/s), C4, or C2 [10,
11]. In some cases, there is an associated immune complex
glomerulonephritis, although these tend to be mild [12, 13].
Deficiency of C3, which occupies a central position in both
alternative and classical pathways, is typically associated with
recurrent pyogenic infections, although glomerulonephritis can
occur in such patients [12, 14]. Since the complement system plays
an important role in immune complex metabolism [15, 16], it
seems likely that patients with early complement protein deficien-
cies process immune complexes abnormally [12, 17]. There are
animals with inherited complete deficiencies of complement
components, such as C4- and C2-deficient guinea pigs, and
C3-deficient dogs [18]. Although most of these animals are
clinically normal, C3-deficient dogs have been reported to develop
membranoproliferative glomerulonephritis [19]. Furthermore,
some C2- and C4-deficient guinea pigs have laboratory evidence
for immune complex disease, such as the presence of serum
rheumatoid factors [20].
To further investigate the role of complement deficiencies in
glomerular disease, we have utilized gene targeting in embryonic
stem cells to generate mice totally deficient in C4 (C4 2/2) or C3
(C3 2/2) [6, 21]. Save for the complement protein deficiency,
unmanipulated C4 2/2 and C3 2/2 animals are phenotypically
normal. In this study, we induced immune complex glomerulone-
phritis in mice by chronic active immunization with the foreign
protein, apoferritin. We show that wild-type, C4 2/2, and C3
2/2 mice have distinct differences in the resultant disease.
METHODS
Animals and disease protocol
Wild-type, C4 2/2, and C3 2/2 mice, all 129SvJ and C57Bl/6
mixed strains, were generated as previously described [6, 21]. All
animals were kept in standard, non-pathogen free housing in the
University of Chicago Animal Care Facility. Immune complex
glomerulonephritis was induced by immunizing 6- to 8-week-old
female mice for 10 weeks with a daily intraperitoneal dose of 4 mg
horse spleen apoferritin (Sigma Chemical Co., St. Louis, MO,
USA), which was dialyzed against phosphate buffered saline
(PBS) and sterile filtered. In previous studies, this high dose of
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antigen led to severe disease in Swiss albino mice [22]. For these
studies, immune complex glomerulonephritis was induced in 13
wild-type, 13 C4 2/2, and 10 C3 2/2 animals. In control studies
performed in parallel, 10 wild-type, 4 C4 2/2, and 7 C3 2/2
animals were immunized with equivalent volumes of PBS alone.
Thus, a total of 57 animals were studied, of which 23 were
wild-type, and 17 each had C4 2/2 and C3 2/2 genotypes. All
animals survived to the end of the protocol. At the end of the
study, an 18-hour urine collection was obtained in metabolic
cages. Animals were then sacrificed by cardiac puncture and
cervical dislocation, and renal tissue was collected for the studies
described below.
Anti-apoferritin ELISA
Polystyrene plates were coated overnight with 5 mg/ml apofer-
ritin in 0.05 M carbonate buffer, pH 9.5. Plates were then washed
3 times with PBS-T (PBS with 0.05% Tween-20) followed by a
blocking step with PBS-T containing 1% BSA (wt/vol) and three
additional washes with PBS-T. Serial dilutions of serum samples,
or affinity purified mouse anti-horse ferritin IgG (Jackson Immu-
noResearch Labs, West Grove, PA, USA) were incubated for two
hours, followed again by three PBS-T washes. Biotinylated-anti-
mouse heavy chain specific antibody (a, g, or m; Sigma) at 1:5000
dilutions were incubated for two hours, followed by three PBS-T
washes. Bound biotinylated anti-mouse immunoglobulins were
detected with streptavidin-horseradish peroxidase (Calbiochem,
San Diego, CA, USA) at a 1:1000 dilution. After washing two
times with PBS-T and three times with water, peroxidase was
developed with o-phenylenediamine, and the OD450 determined.
All steps were performed at room temperature, except when
dissolved cryoprecipitates were analyzed (see below), in which
case, the antibody step was performed at 37°C.
To determine whether formation of apoferritin-anti-apoferritin
immune complexes affected antibody measurements by ELISA,
the following in vitro assay was performed. Anti-ferritin IgG was
mixed with amounts of free apoferritin ranging from 60-fold
antibody excess to 15-fold antigen excess. After a 30 minute
incubation at 37°C, this mixture was subjected to anti-apoferritin
ELISA.
Cryoprecipitate analysis
Blood collected from animals by cardiac puncture was allowed
to clot at 37°C and then sera were isolated and stored for five days
at 4°C. Sera were then examined for the presence of cryoprecipi-
tates. To characterize the immunoglobulin content of cryoprecipi-
tates, sera were centrifuged at 16,000 3 g and cryoprecipitates
were washed with cold PBS. Cryoprecipitates were then dissolved
in PBS at 37°C. Immunofixation electrophoresis [23] was per-
formed using a Beckman Instruments’ Paragon system (Fullerton,
CA, USA) according to the manufacturer’s instructions. Five
microliter samples were applied to individual lanes of the agarose
gel. Following electrophoretic separation, anti-mouse heavy chain
specific antibodies (a, g, or m; Sigma) were applied to separate
lanes. Gels were washed, stained, destained and then dried. The
presence of IgA, IgG, and IgM was visually assessed.
Urinary albumin and creatinine determinations
To measure urinary albumin, we used the protocol described by
Mayadas et al [24]. Microtiter plates were coated overnight with 5
mg/ml affinity purified goat anti-mouse albumin (Bethyl Labora-
tories, Montgomery, TX, USA) in 0.05 M carbonate buffer, pH
9.5. Wells were washed with PBS-T and blocked with PBS-T with
1% BSA. Serial dilutions of urine, or a mouse albumin standard
(Sigma) in PBS-T were incubated for two hours, followed by three
washes with PBS-T. Subsequently, horseradish peroxidase-labeled
affinity purified goat anti-mouse albumin (Bethyl Laboratories) at
1:1000 in PBS-T was incubated for two hours. Following washing
with PBS-T and water, peroxidase was detected with o-phenylene-
diamine, and the OD450 determined. In our hands, this assay was
linear from 1 to 100 ng/ml mouse albumin. Urine and serum
creatinine concentrations were determined with a Beckman Au-
toanalyzer. To normalize urinary albumin excretion, data are
expressed as mg urinary albumin/mg urinary creatinine.
Histology and glomerular nuclear counts
Renal cortical tissue for light microscopy was fixed in buffered
formalin. Five micrometer sections were cut and stained with
PAS. For each individual animal, nine photographs at 3200
magnification were taken of random areas of cortex which in-
cluded 1 to 4 glomeruli, and then the 35 mm slides were converted
to TIFF files using a Polaroid Sprint Scan (Cambridge, MA, USA)
at a resolution of 2700 dots per inch. Glomerular nuclear counts
were obtained on a computer monitor screen using Photoshop
software (Adobe Systems Inc., San Diego, CA, USA). Only
equatorially sectioned glomeruli were counted. All slides were
coded so that the origin of the tissue was unknown to the observer.
Immunohistochemistry and immunofluorescence microscopy
Tissue was snap frozen in isopentane on dry ice. Four micro-
meter cryostat sections were processed for direct immunofluores-
cence (IF) microscopy as described previously [25]. Fluorescein
isothiocyanate-conjugated antibodies to mouse C3, and heavy
chain specific antibodies to mouse a, g, and m chains were
obtained from Cappel (Organon Teknika Corp., Durham, NC,
USA). For use in double-label immunofluorescence, anti-mouse
C3 (Cappel) was tetramethylrhodamine-conjugated using a kit
from Pierce Chemical Co. (Rockford, IL, USA). At least 30
glomeruli from each animal were examined, and a semiquantita-
tive score of staining intensity and distribution from 0 to 41 was
given, as previously detailed [26]. Glomeruli were visualized and
photographed with a BX-60 immunofluorescence microscope and
a PM-30 Exposure Control Unit (Olympus Optical Co., Ltd.,
Tokyo, Japan). Illustrative staining patterns are shown in Figures
2C (11), 3A (21), and 3B (31). For immunohistochemistry,
sections were fixed with 4% paraformaldehyde. Monoclonal anti-
bodies F4/80 and 7/4 (Serotec, Ltd., Oxford, UK) were used to
detect mouse macrophages and neutrophils, respectively. The
ABC staining kit from Vector Laboratories (Burlingame, CA,
USA) was used according to the manufacturer’s instructions. The
number of positively stained cells in at least 50 glomeruli per
animal were counted. In each of these instances, the observer was
blinded as to the origin of the individual specimen.
Electron microscopy
For electron microscopy, 1 mm3 blocks of renal cortical tissue
were fixed in 2.5% glutaraldehyde in 1.87% sodium phosphate
buffer, pH 7.4, washed with this same buffer, and post-fixed in 1%
OsO4. The tissue was dehydrated in graded ethanols followed by
propylene oxide, and embedded in Epon. One-micrometer sec-
tions were prepared from each block and stained with toluidine
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blue to visualize the tissue prior to preparation of ultrathin
sections; the latter sections prepared from each block contained at
least two glomeruli. Ultrathin sections were stained with uranyl
acetate and lead citrate and were viewed in a Philips CM10
electron microscope. Tissues were coded so that their origin was
unkown to the observer.
Statistics
Statistical analyses were performed with the Minitab software
(College Park, PA, USA). Data are expressed as mean 6 SEM. For
each variable, the experimental and control groups were com-
pared by one-way analyses of variance. When a significant differ-
ence (P , 0.05) was identified, individual groups were compared
using Fisher’s pairwise comparisons, with an individual error
rate # 0.02 considered statistically significant.
To determine if any of the measured variables were correlated
within a specific experimental group of animals, Pearson’s corre-
lation was employed. Those variables that were correlated were
then examined by regression analysis for statistical significance.
RESULTS
Antibody response to chronic immunization with apoferritin
In this study, mice were immunized daily with high doses of the
exogenous protein apoferritin. Wild-type, C4 2/2, and C3 2/2
animals developed anti-apoferritin IgM and IgG antibodies (Ta-
ble 1). On average, wild-type animals had higher concentrations of
IgM antibodies, but these were not different statistically from C4
2/2 and C3 2/2 animals. In contrast, wild-type mice immunized
with apoferritin had significantly greater anti-apoferritin IgG
antibody levels measured by ELISA than C4 2/2 or C3 2/2
mice. Nonetheless, anti-apoferritin IgG antibodies were detect-
able in every animal. Specific anti-apoferritin IgA antibodies
could not be detected in animals from any group.
To determine the effect of immune complexes on the measure-
ment of anti-apoferritin antibody levels, we performed a study in
which various quantities of apoferritin were added to anti-
apoferritin IgG in vitro. As shown in Figure 1, measured anti-
apoferritin IgG declined by ;75% when antigen excess was
reached, indicating that antibody in immune complexes was not
measured effectively. Since the primary focus of this study was on
the renal effects of chronic serum sickness, we did not suspend
antigen administration in animals to allow clearance of the ;450
kDa apoferritin and immune complexes prior to assessing anti-
body titers.
At sacrifice, all 13 C4 2/2 and 10 C3 2/2 animals immunized
with apoferritin had easily detectable cryoprecipitates. Immuno-
chemical characterization revealed polyclonal IgM and IgG in
each C4 2/2 cryoprecipitate. In the C3 2/2 animals, polyclonal
IgM was present in all samples, while polyclonal IgG was variably
present. In only a single wild-type animal immunized with apof-
erritin and one C4 2/2 animal immunized with PBS were
cryoprecipitates identified, both of which were small. In these,
polyclonal IgM was faintly detectable and IgG was absent. IgA
was not detected in any cryoprecipitate.
The presence of anti-apoferritin antibodies in cryoprecipitates
was evaluated by dissolving cryoprecipitates and performing the
ELISA at 37°C. By this analysis, all cryoprecipitates contained
detectable anti-apoferritin IgG and IgM antibodies. In the case of
anti-apoferritin IgG, the cryoprecipitates contained from 0.09 to
3.33 mg IgG antibody, corresponding to a concentration of 0.23 to
8.33 mg/ml in the original sera. Notably, the measured anti-
apoferritin IgG and IgM concentrations in cryoprecipitates did
not correlate with the measured sera levels. These data illustrate
the limitations in drawing conclusions from antibody measure-
ments alone, particularly in the C4 2/2 and C3 2/2 animals, all
of which had cryoprecipitates.
Glomerular immunofluorescence and electron microscopy
Wild-type animals immunized with apoferritin developed im-
mune complex glomerulonephritis characterized by mesangial
deposition of IgG, IgM, IgA and C3 (panel A in Figs. 2 to 5),
which for all except IgA staining were statistically greater than the
findings in wild-type animals immunized with PBS. Graphical
scoring of IF data for all groups of animals is shown in Figure 6.
Ten out of 13 wild-type animals also had finely granular periph-
eral capillary wall deposits of IgG (Fig. 2E), which in 50% of
animals was associated with faint (1⁄2 to 11⁄21) C3 staining as
determined by double-labeling immunofluorescence.
C4 2/2 and C3 2/2 animals immunized with apoferritin had
distinctly different patterns of glomerular IF staining. In C4 2/2
immunized with apoferritin, IgG staining was absent in 10 out of
13 animals while two others had only trace mesangial staining
(Fig. 2B), and a single C4 2/2 animal had 31 mesangial IgG
staining. C3 2/2 immunized animals had staining for mesangial
IgG that was detectable, but was to a lesser extent than that of the
wild-type animals (Fig. 2C). In contrast to apoferritin-immunized
wild-type animals, peripheral capillary wall IgG staining was not
identified in any of the C4 2/2 or C3 2/2 animals. A similar low
level of glomerular IgG staining was seen in C4 2/2 and C3 2/2
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Fig. 1. Effect of increasing apoferritin input on the measurement of
anti-apoferritin IgG antibodies. Anti-apoferritin IgG (1 mg/ml) was
incubated with increasing amounts of free apoferritin, followed by deter-
mination of anti-apoferritin IgG by ELISA. Each data point is the average
of three measurements.
Table 1. Anti-apoferritin antibody levels
Anti-apoferritin IgG
ng/ml
Anti-apoferritin IgM
OD450 units/ml
Wild-type mice 88.8 6 12.2a (29.3–185.0) 193.4 6 28.4 (63.0–424.2)
C4 2/2 mice 27.1 6 3.3 (5.3–40.9) 150.4 6 14.6 (78.0–261.6)
C3 2/2 mice 24.7 6 3.9 (11.1–52.2) 152.6 6 23.2 (42.6–237.0)
Data are mean 6 SEM with the range given in the parentheses.
a P , 0.001 vs. C4 2/2 and C3 2/2 mice
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animals immunized with PBS, with no statistical differences
between these animals and those C4 2/2 and C3 2/2 mice
immunized with apoferritin. Figure 2D shows a representative
glomerulus from one of the PBS-immunized C4 2/2 animals, all
four of which had 11 staining for IgG.
In apoferritin-immunized C4 2/2 and C3 2/2 mice, intense
mesangial staining for IgM was present (Fig. 3B and C), which was
significantly greater than in wild-type animals. All three groups
of animals immunized with PBS also had mesangial IgM
deposits (Fig. 3D), but these were significantly less than
apoferritin-immunized animals. We have also seen such mesan-
gial IgM in unmanipulated animals, so this cannot be ascribed to
the experimental protocol.
As noted above, apoferritin-immunized wild-type animals had
Fig. 2. Immunofluorescence staining for IgG in representative glomeruli. Apoferritin-immunized wild-type mice (A, E), apoferritin-immunized C4
2/2 mice (B), apoferritin-immunized C3 2/2 mice (C), and PBS-immunized C4 2/2 mice (D) (magnification 3400 A-D, 31000 E).
Fig. 3. Immunofluorescence staining for IgM
in representative glomeruli. Apoferritin-
immunized wild-type mice (A), apoferritin-
immunized C4 2/2 mice (B), apoferritin-
immunized C3 2/2 mice (C), and PBS-
immunized C4 2/2 mice (D) (magnification
3400).
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detectable mesangial IgA staining (Fig. 4A), but this was not
statistically different from that of PBS-immunized wild-type ani-
mals. Among apoferritin-immunized animals, both C4 2/2 and
C3 2/2 groups had significantly greater IgA deposition than
PBS-immunized controls (Figs. 4B and C). The IgA deposition in
C3 2/2 animals was statistically greater than that of all other
animals. All PBS-immunized animals had minimal IgA staining
(Fig. 4D).
Despite the absence of C4, all C4 2/2 mice had 11 to 31
mesangial staining for C3 (Fig. 5B), and this was undistinguish-
able from wild-type mice (Fig. 5A). Since C4 2/2 mice cannot
activate the classical pathway of complement, this indicates that
the alternative pathway was activated in these animals. As ex-
pected, C3 2/2 mice had absent C3 staining (Fig. 5C). In
addition, the intermittent Bowman’s capsule and tubular base-
ment membrane staining for C3 seen in all animals, including
PBS-immunized C4 2/2 mice (Fig. 5D) was absent in every C3
2/2 animal. Thus, C3 appears to be activated by the alternative
Fig. 4. Immunofluorescence staining for IgA
in representative glomeruli. Apoferritin-
immunized wild-type mice (A), apoferritin-
immunized C4 2/2 mice (B), apoferritin-
immunized C3 2/2 mice (C), and PBS-
immunized C4 2/2 mice (D) (magnification
3400).
Fig. 5. Immunofluorescence staining for C3 in
representative glomeruli. Apoferritin-
immunized wild-type mice (A), apoferritin-
immunized C4 2/2 mice (B), apoferritin-
immunized C3 2/2 mice (C), and PBS-
immunized C4 2/2 mice (D) (magnification
3400).
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pathway in the interstitial compartment, as others have speculated
[27, 28].
It should be noted that while the IF data are semiquantitative,
the pattern of IF staining was unique for each of the six groups of
animals. That is, given slides from an unknown animal that were
stained for IgG, IgM, IgA, and C3, it was an easy matter to
determine from which group the tissue emanated.
By electron microscopy, electron dense deposits were present in
mesangial areas of all apoferritin-immunized wild-type, C4 2/2,
and C3 2/2 animals (Fig. 7A). In the wild-type animals, subepi-
thelial deposits with focal foot process effacement (Fig. 7B) and
subendothelial deposits (Fig. 7C) were apparent in glomeruli from
all four animals examined. In apoferritin-immunized C4 2/2
animals, subepithelial and subendothelial deposits were seen in 1
of 10 glomeruli from four mice, the positive glomerulus emanating
from the C4 2/2 animal with 31 mesangial IgG staining by IF
microscopy. In three apoferritin-immunized C3 2/2 animals, rare
small subendothelial and subepithelial deposits were seen in 1 of
7 and 5 of 7 glomeruli, respectively. There was also focal foot
process effacement noted, which was not necessarily in areas of
deposits (Fig. 7A, arrow). Consistent with the IF data, PBS-
immunized C4 2/2 animals also had mesangial electron-dense
deposits, although these were less than in animals immunized with
apoferritin.
Assessment of glomerular disease
Mesangial hypercellularity was evident in all apoferritin-immu-
nized animals (Figs. 8A-C). However, since control mice often-
times also appear to have mild mesangial hypercellularity (Fig.
8D), this was quantified more accurately by glomerular cell
counts. By this analysis, wild-type and C4 2/2 animals immunized
with apoferritin had significantly more cells per glomerulus than
the same animals immunized with PBS (Fig. 9), while apoferritin-
immunized C3 2/2 animals did not have increased cellularity
compared to their controls. Interestingly, PBS-immunized C4
2/2 and C3 2/2 animals had significantly more glomerular cells
compared with PBS-immunized wild-type animals. Increased mes-
angial matrix was also seen in apoferritin-immunized animals,
being most pronounced in C4 2/2 and C3 2/2 animals. Al-
though these animals also had increased mesangial IgM compared
to apoferritin-immunized wild-type mice, suggesting these two
variables might be related, there was no correlation between the
IgM staining score and a semiquantitative score for matrix
expansion.
For glomerular neutrophil counts, the only group that had a
significant increase was apoferritin-immunized C4 2/2 mice,
which had 0.24 6 0.03 neutrophils per glomerulus, this being
statistically greater than apoferritin-immunized wild-type mice
(0.09 6 0.01) and PBS-immunized C4 2/2 mice (0.10 6 0.01).
The presence of glomerular macrophages was decidedly rare in all
groups, with only single monoclonal antibody F4/80-positive cells
being found in 40 to 80 glomeruli in all groups. Such low
macrophage counts in normal animals have been seen by others,
as well as in the anti-glomerular basement membrane nephritis
model in mice [29].
Urinary albumin excretion was mildly elevated in all groups of
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Fig. 6. Scores for IgG (A), IgM (B), IgA (C), and C3 (D) staining by immunofluorescence microscopy in wild-type (f), C4 2/2 (o), and C3 2/2 mice
(s) immunized with apoferritin and PBS. In each case, the groups were statistically different by one-way analysis of variance. Individual comparisons
were made by Fisher’s pairwise comparisons, and statistically significant differences are indicated. P , 0.02 vs.: ¶matched PBS-immunized control;
*apoferritin-immunized wild-type, §apoferritin-immunized C3 2/2.
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animals actively immunized with apoferritin (29.3 6 3.5, 30.1 6
3.1, and 33.8 6 3.1 mg creatinine/mg albumin in wild-type, C4
2/2, and C3 2/2 animals, respectively) but only the values from
C3 2/2 animals were statistically different from those of PBS-
immunized wild-type or C3 2/2 animals (20.3 6 1.4 and 17.4 6
2.7 mg creatinine/mg albumin). Serum creatinine levels were
normal in all groups of animals, with mean values 0.24 to 0.31
mg/dl.
Correlations among data
Data were analyzed to determine whether any of the histolog-
ical or disease variables were related. In wild-type mice immu-
nized with apoferritin, there was a strong correlation between
mesangial IgG and C3 deposition (Fig. 10A; r 5 0.92, P , 0.001),
suggesting that mesangial IgG activated complement. In contrast,
in apoferritin-immunized C4 2/2 animals there was no relation-
ship between glomerular IgG, IgM, or IgA and glomerular C3
staining. However, in this group, there was a significant positive
correlation between mesangial C3 deposition and glomerular
nuclear counts (Fig. 10B; r 5 0.62, P 5 0.023). In apoferritin-
immunized C3 2/2 animals, glomerular nuclear counts were
positively correlated with mesangial IgM scores (r 5 0.67; P 5
0.033; not shown). No other correlations were noted.
DISCUSSION
In this study, we have examined the roles of C4 and C3 in a
model of immune complex glomerulonephritis induced by active
immunization with apoferritin. Wild-type animals with an intact
complement system produced anti-apoferritin IgG and IgM anti-
bodies, and developed mesangial proliferative glomerulonephri-
tis, characterized by hypercellularity, matrix expansion, deposition
of IgG, IgM, IgA and C3, and the presence of electron dense
deposits. In the majority of animals, the peripheral capillaries also
contained IgG, C3 and subendothelial and subepithelial electron
dense deposits. Thus, this model is typical of immune complex
glomerulonephritis, of which lupus nephritis is the prototype.
Actively immunized C4 2/2 and C3 2/2 animals also developed
immune complex glomerulonephritis, but their disease manifes-
tations were distinctly different from that of their wild-type
littermates. In these animals, IgG was either absent or present in
reduced quantities in glomeruli, yet IgM and IgA were present in
greater intensity in glomeruli, and the mesangial proliferation was
of equal or greater severity than the wild-type animals.
Despite the absence of C4, and the consequent inability to
activate the classical pathway of complement, C4 2/2 animals
had glomerular C3 staining equivalent to that of the wild-type
animals. Given the lack of C4 in C4 2/2 animals, and the
consequent inability to activate the classical pathway, this indi-
cates that the alternative pathway of complement was activated in
these animals. Although IgG in immune complexes is capable of
activating the alternative pathway [30], IgG was not detectable in
glomeruli of the majority of these animals, and therefore, is
unlikely to be involved in complement activation. It is, however,
conceivable that mesangial IgA, which was present in C4 2/2
glomeruli, activated C3 via the alternative pathway [31].
The positive correlation between C3 staining intensity and
Fig. 7. Ultrastructural appearances of glomeruli from apoferritin-immunized C3 2/2 mice (A) and apoferritin-immunized wild-type mice (B and C).
Mesangial electron dense deposits were present in apoferritin-immunized C3 2/2 mice (asterisks), but the peripheral capillary loops were free of
deposits. Subepithelial (B, arrow) and subendothelial deposits (C, arrow) were present in apoferritin-immunized wild-type mice (magnifications: A,
38200; B, 323,400; C, 39000).
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glomerular cellularity in the C4 2/2 animals suggests that com-
plement has a role in this process. Such a role for complement,
and in particular, the C5b-9 membrane attack complex, in medi-
ating mesangial cell proliferation has been shown in a rat model of
mesangial proliferative glomerulonephritis [32, 33]. Consistent
with a role of complement to result in glomerular cell prolifera-
tion is that apoferritin-immunized C3 2/2 animals did not have
increased cellularity compared to PBS-immunized C3 2/2 ani-
mals. Interestingly, apoferritin-immunized C4 2/2 animals also
had a significant increase in glomerular neutrophils, although the
absolute numbers were small and did not account for the bulk of
increased cells in glomeruli. Although the complement activation
products C3b, C3a, and C5a can recruit and activate neutrophils,
it is not clear whether the observed glomerular neutrophil in-
crease was due to an effect of the complement system, because
there was no correlation between neutrophil counts and glomer-
ular C3 deposition in apoferritin-immunized C4 2/2 animals.
Furthermore, wild-type animals with comparable C3 deposition
did not have a similar increase in glomerular neutrophils.
Our findings suggest that complement is involved in the
pathogenesis of immune complex glomerulonephritis, which sup-
ports earlier observations made by Falk and Jennette in this
model [34]. In these studies, C5 deficient B.10.D2.OSN mice were
compared with congenic C5 sufficient B.10.D2.NSN animals. No
difference in anti-apoferritin levels were detected between the
two groups. However, disease manifestations were significantly
reduced in C5 deficient animals, as measured by glomerular and
tubulointerstitial pathology and by serum creatinine concentra-
tions. Nonetheless, there still was detectable disease in some of
Fig. 8. Histological appearances of representative glomeruli. Figures are from apoferritin-immunized wild-type mice (A), apoferritin-immunized C4
2/2 mice (B), apoferritin-immunized C3 2/2 mice (C), and PBS-immunized C4 2/2 mice (D) (magnification 3400).
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Fig. 9. Glomerular cell counts in wild-type (f), C4 2/2 (o), and C3 2/2
(s) mice immunized with apoferritin and PBS. The groups were statisti-
cally different by one-way analysis of variance. Individual comparisons
were made by Fisher’s pairwise comparisons, and statistically significant
differences are indicated. P , 0.02 vs.: ¶matched PBS-immunized control;
*apoferritin-immunized wild-type, §apoferritin-immunized C3 2/2;
#PBS-immunized wild-type.
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the C5 deficient B.10.D2.OSN animals in association with glomer-
ular deposition of immune complexes and C3. These results
indicate that immune complex glomerulonephritis is mediated in
part by C5a recruitment and activation of inflammatory cells,
and/or by C5b-9 mediated glomerular cell injury with resultant
proliferative events [33]. Since disease was not completely elimi-
nated in C5 deficient animals, proximal complement components,
such as the C3a and C3b cleavage products of C3, or non-
complement mediators of disease must also be playing a role in
this model of glomerulonephritis [34]. The finding of C5-indepen-
dent, yet C3-dependent disease has been observed in another
murine model of immune complex glomerulonephritis, in which
mice were immunized with cationized bovine serum albumin [35].
It has long been appreciated that complement activation is key
to mount a proper humoral immune response to an administered
antigen. This has been shown by studies in which C3 has been
depleted with cobra venom factor [36], and by studies in congen-
itally C4-, C2-, and C3-deficient humans and animals [37–39]. Our
recent data with the same C4 2/2 and C3 2/2 mice used in the
current studies have extended these observations [6]. A major
factor in the complement enhancement of the humoral response
is covalent attachment of classical pathway-activated C3 to anti-
gen which results in coligation of the CD21/CD19/TAPA-1 core-
ceptor complex with the B lymphocyte receptor [3–5]. A consis-
tent theme in these studies is that the impaired antibody response
can be partially overcome by increasing the antigen dose. Thus, we
reasoned that the high dose of antigen used in the current study
might bypass the complement dependence of the humoral im-
mune response. Although there was no difference between wild-
type, C4 2/2 and C3 2/2 anti-apoferritin IgM antibody levels,
C4 2/2 and C3 2/2 had serum anti-apoferritin IgG concentra-
tions that were roughly 1⁄3 that of wild-type animals. However, it is
difficult to draw firm conclusions about these levels, given the
presence of cryoprecipitates in C4 2/2 and C3 2/2 animals,
which contained anti-apoferritin antibodies that in some cases
were in considerable excess of those found in wild-type sera. The
latter findings show that the C4 2/2 and C3 2/2 animals did not
have a suboptimal humoral immune response to the administered
apoferritin.
The effect of complement activation on immune complex
processing is complicated. Complement activation can both solu-
bilize and inhibit the precipitation of immune complexes [17, 40].
The presence of cryoprecipitates in all apoferritin-immunized C4
2/2 and C3 2/2 animals is consistent with this role of comple-
ment to keep immune complexes in solution. Furthermore, C4b
and C3b on immune complexes interact with complement recep-
tors on primate erythrocytes and non-primate platelets [41–43],
which appear to facilitate their clearance by the mononuclear
phagocyte system [16]. In this study, IgG deposited in mesangial,
subendothelial, and subepithelial locations of wild-type animals.
In contrast, despite the presence of anti-apoferritin IgG antibod-
ies in all actively-immunized C4 2/2 and C3 2/2 animals, little to
no glomerular deposition of IgG was evident in the C4 2/2
animals and an intermediate amount of glomerular IgG was found
in C3 2/2 animals. Taken together, these data suggest that
classical pathway complement activation facilitates deposition of
IgG-containing immune complexes in the mesangium and periph-
eral capillary wall of the glomerulus. Evidently, activation up to
C4 leads to partial deposition in glomeruli. Whether these effects
are related to the sizes of the complexes [44], which should be
smaller in the wild-type complement-replete animals, and/or to
interactions with resident glomerular or blood cell complement
receptors [43, 45, 46] remains to be defined.
In contrast to IgG, IgM was present in greater intensity in the
mesangial areas of actively-immunized C4 2/2 and C3 2/2
animals compared to the wild-type mice. These results suggest
that activation of the classical pathway through C3 facilitates the
clearance of IgM-containing immune complexes in wild-type
animals. Lastly, IgA was significantly greater in apoferritin-immu-
nized C3 2/2 mice compared to all other groups. Since IgA-
containing immune complexes have been reported to directly
activate C3 via the alternative pathway [31], it may be that an
intact alternative pathway, present in wild-type and C4 2/2
animals, is sufficient to effectively clear IgA. It should be noted
that no specific anti-apoferritin IgA antibodies were detected, nor
was IgA found in any of the cryoprecipitates, so the origin of the
glomerular IgA is not clear. It is also possible that local synthesis
of C3 secondary to the inflammatory response resulted in C3
deposition independent of IgA [47–49].
The results of these studies have relevance to human disease.
The association between hereditary deficiencies of early comple-
ment components and immune complex diseases is well known.
Although congenital deficiencies of C4 or C3 are rare, associated
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Fig. 10. Correlations between mesangial IgG and C3 staining in apofer-
ritin-immunized wild-type mice (A) and mesangial C3 staining and
glomerular cellularity in apoferritin-immunized C4 2/2 mice (B).
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glomerulonephritis has been reported in these patients [13, 50,
51]. In the cases of early complement component deficiencies, it
has been difficult to ascribe a pathogenic potential to complement
activation in these conditions in which immune complexes deposit
in tissue, as it is expected that complement activation cannot
occur. Here we show that C3 does deposit in the mesangium of all
C4 2/2 animals, and that it is correlated with mesangial hyper-
cellularity. While complement activation is unlikely to be the sole
mediator of glomerular injury, it is likely to play a role in the
glomerular injury seen. The results of our studies illustrate the
complex interplay between the anti- and pro-inflammatory effects
of the complement system in immune complex diseases affecting
the glomerulus.
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